CN100393714C - 促旋酶抑制剂及其用途 - Google Patents

促旋酶抑制剂及其用途 Download PDF

Info

Publication number
CN100393714C
CN100393714C CNB2004800030868A CN200480003086A CN100393714C CN 100393714 C CN100393714 C CN 100393714C CN B2004800030868 A CNB2004800030868 A CN B2004800030868A CN 200480003086 A CN200480003086 A CN 200480003086A CN 100393714 C CN100393714 C CN 100393714C
Authority
CN
China
Prior art keywords
compound
ring
group
independently selected
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800030868A
Other languages
English (en)
Chinese (zh)
Other versions
CN1745077A (zh
Inventor
P·S·查利弗森
D·D·德尹因格
A-L·戈里罗特
廖友胜
S·M·隆金
D·司塔莫斯
E·皮罗拉
王天生
A·雷特兰
J·德鲁姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN1745077A publication Critical patent/CN1745077A/zh
Application granted granted Critical
Publication of CN100393714C publication Critical patent/CN100393714C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB2004800030868A 2003-01-31 2004-01-29 促旋酶抑制剂及其用途 Expired - Fee Related CN100393714C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44391703P 2003-01-31 2003-01-31
US60/443,917 2003-01-31

Publications (2)

Publication Number Publication Date
CN1745077A CN1745077A (zh) 2006-03-08
CN100393714C true CN100393714C (zh) 2008-06-11

Family

ID=34115255

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800030868A Expired - Fee Related CN100393714C (zh) 2003-01-31 2004-01-29 促旋酶抑制剂及其用途

Country Status (24)

Country Link
US (3) US7495014B2 (https=)
EP (1) EP1592686B1 (https=)
JP (2) JP4691033B2 (https=)
KR (1) KR20060056270A (https=)
CN (1) CN100393714C (https=)
AR (1) AR042956A1 (https=)
AT (1) ATE435859T1 (https=)
AU (1) AU2004261545B2 (https=)
CA (1) CA2513463C (https=)
CY (1) CY1109385T1 (https=)
DE (1) DE602004021904D1 (https=)
DK (1) DK1592686T3 (https=)
ES (1) ES2327642T3 (https=)
IL (1) IL169720A (https=)
MX (1) MXPA05008126A (https=)
MY (1) MY139124A (https=)
NO (1) NO20053845L (https=)
NZ (1) NZ541885A (https=)
PT (1) PT1592686E (https=)
RU (1) RU2350612C2 (https=)
SI (1) SI1592686T1 (https=)
TW (1) TWI334416B (https=)
WO (1) WO2005012292A1 (https=)
ZA (1) ZA200505773B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106167486A (zh) * 2015-05-22 2016-11-30 山东轩竹医药科技有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
CN105884752B (zh) * 2015-02-13 2018-08-31 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374191A1 (en) * 2002-06-13 2005-10-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7863335B2 (en) * 2004-07-23 2011-01-04 The University Of Medicine And Dentistry Of New Jersey Non-antibiotic intervention of chlamydial infection
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
DE102005028862A1 (de) * 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JP2009514894A (ja) * 2005-11-07 2009-04-09 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレース阻害剤としてのベンズイミダゾール誘導体
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
WO2009001915A1 (ja) * 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
WO2009027733A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
EP2229379A2 (en) 2007-12-07 2010-09-22 Vertex Pharmaceuticals Incorporated Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1h-benzo[d]imidazol-2-yl)urea
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
TW200940537A (en) * 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
EP2300463A1 (en) 2008-06-04 2011-03-30 AstraZeneca AB Heterocyclic urea derivatives for the treatment of bacterial infections
EP2321309A1 (en) * 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
CN102369186B (zh) * 2009-04-02 2014-07-09 默克专利有限公司 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物
US20120149710A1 (en) * 2009-08-24 2012-06-14 The Regents Of The University Of California Sortase a inhibitors
US20110120915A1 (en) * 2009-11-24 2011-05-26 Chevron U.S.A. Inc. Hydrogenation of solid carbonaceous materials using mixed catalysts
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US20150174137A1 (en) * 2010-06-02 2015-06-25 Alcon Research, Ltd. Compositions for treating microbial infections
RU2609259C2 (ru) 2011-01-14 2017-01-31 Сперо Тринем, Инк. Пиримидиновые ингибиторы гиразы и топоизомеразы iv
KR101882172B1 (ko) 2011-01-14 2018-07-26 스페로 트리넴, 인코포레이티드 자이라제 및 토포이소머라제 ⅳ 억제제의 제조방법
US8476281B2 (en) * 2011-01-14 2013-07-02 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea
BR112013017977A2 (pt) * 2011-01-14 2019-09-24 Vertex Pharma formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia
CN103702994B (zh) * 2011-06-20 2016-03-23 沃泰克斯药物股份有限公司 旋转酶和拓扑异构酶抑制剂的磷酸酯
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SI3010503T1 (sl) * 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
US20170007615A1 (en) 2014-02-03 2017-01-12 Biota Europe Ltd Antibacterial Compounds
EP2913330A1 (en) * 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
EP3298005B1 (en) 2015-05-21 2024-01-24 The Regents of The University of California Anti-cancer compounds
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
CA3057431A1 (en) 2017-03-24 2018-09-27 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114981260A (zh) * 2019-12-19 2022-08-30 斯特拉斯堡大学 σ-1受体配体及其用途
KR102919045B1 (ko) * 2022-06-09 2026-01-29 한국화학연구원 벤즈이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 또는 감염증의 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
WO2003105846A1 (en) * 2002-06-13 2003-12-24 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015676A1 (de) * 1970-04-02 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel
US4174400A (en) 1978-09-13 1979-11-13 Merck & Co., Inc. Anthelmintic benzimidazoles
US4512998A (en) 1980-10-20 1985-04-23 Schering Corporation Anthelmintic benzimidazole carbamates
CA2028530A1 (en) 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
DE69220744T2 (de) * 1991-09-27 1997-11-13 Merrell Pharma Inc 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
GB9911594D0 (en) 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US7582641B2 (en) * 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) * 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
JP2009514894A (ja) 2005-11-07 2009-04-09 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレース阻害剤としてのベンズイミダゾール誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
WO2003105846A1 (en) * 2002-06-13 2003-12-24 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SYNTHESIS AND ANTIMICROBIAL ACTIVITIESOF5-FLUORO-1,2,6-TRISUBSTITU TEDBENZIMIDAZOLECARBOXAMIDEAND ACETAMIDEDERIVATIVES. KUS C ET AL:.ARCHIV DER PHARMAZIE,Vol.334 No.11. 2001
SYNTHESIS AND ANTIMICROBIAL ACTIVITIESOF5-FLUORO-1,2,6-TRISUBSTITU TEDBENZIMIDAZOLECARBOXAMIDEAND ACETAMIDEDERIVATIVES. KUS C ET AL:.ARCHIV DER PHARMAZIE,Vol.334 No.11. 2001 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105884752B (zh) * 2015-02-13 2018-08-31 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂
CN106167486A (zh) * 2015-05-22 2016-11-30 山东轩竹医药科技有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂

Also Published As

Publication number Publication date
SI1592686T1 (sl) 2009-12-31
IL169720A (en) 2011-08-31
TWI334416B (en) 2010-12-11
AU2004261545B2 (en) 2010-06-24
JP2011046745A (ja) 2011-03-10
AR042956A1 (es) 2005-07-13
PT1592686E (pt) 2009-08-25
EP1592686A1 (en) 2005-11-09
US20090176771A1 (en) 2009-07-09
RU2005127328A (ru) 2006-02-10
RU2350612C2 (ru) 2009-03-27
US7495014B2 (en) 2009-02-24
EP1592686B1 (en) 2009-07-08
AU2004261545A1 (en) 2005-02-10
ATE435859T1 (de) 2009-07-15
DK1592686T3 (da) 2009-10-19
NZ541885A (en) 2009-01-31
ES2327642T3 (es) 2009-11-02
ZA200505773B (en) 2006-09-27
JP4691033B2 (ja) 2011-06-01
CY1109385T1 (el) 2014-07-02
NO20053845L (no) 2005-08-16
DE602004021904D1 (de) 2009-08-20
CA2513463A1 (en) 2005-02-10
JP2006528677A (ja) 2006-12-21
US8188095B2 (en) 2012-05-29
WO2005012292A1 (en) 2005-02-10
KR20060056270A (ko) 2006-05-24
CN1745077A (zh) 2006-03-08
TW200503708A (en) 2005-02-01
HK1087699A1 (zh) 2006-10-20
US20130023525A1 (en) 2013-01-24
MY139124A (en) 2009-08-28
MXPA05008126A (es) 2006-03-30
US20040235886A1 (en) 2004-11-25
CA2513463C (en) 2012-07-10

Similar Documents

Publication Publication Date Title
CN100393714C (zh) 促旋酶抑制剂及其用途
RU2333208C2 (ru) Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций
RU2262932C2 (ru) Ингибиторы гиразы бактерий и их применения
EP1789419B1 (en) Gyrase inhibitors and uses thereof
JP2006528677A5 (https=)
CN115843295B (zh) Nampt调节剂
CN101538263A (zh) 作为促旋酶和/或拓扑异构酶iv的抑制剂用于治疗细菌感染的2－脲基－6－杂芳基－3h－苯并咪唑－4－羧酸衍生物和相关化合物
WO2022135534A1 (zh) 取代的含氮双环化合物及其用途
HK1087699B (en) Gyrase inhibitors and uses thereof
AU2002246684A1 (en) Bacterial gyrase inhibitors and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087699

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1087699

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080611

Termination date: 20150129

EXPY Termination of patent right or utility model